Gemini Therapeutics, Inc.

FS Development Corp. (Nasdaq: FSDC), a blank-check company sponsored by Foresite Capital Management, completed its business combination with Gemini Therapeutics, Inc., a clinical-stage biotechnology company focused on genetic medicines for age-related eye diseases including geographic atrophy. FSDC priced its initial public offering in 2020 and announced the Gemini Therapeutics transaction in October of that year. The deal is now closed, bringing Gemini Therapeutics to the public markets through the SPAC vehicle within the broader biotech and pharmaceutical sector. Visit SpacDesk and sign up for a free account to access the full deal timeline, filing history, and analytics for FSDC and hundreds of other SPAC transactions.

SPAC Counterparty (1)